Peter Hunt, MD

Headshot of Peter Hunt
User Profile Photo

Peter Hunt, MD

User Profile Name
Co-Director, UCSF-Bay Area CFAR
Professor, School of Medicine
User Profile Title
User Profile Email

Biography

Peter Hunt is a Professor of Medicine in the Division of Experimental Medicine (DEM) at the University of California San Francisco. He also serves as Associate Chief for Research for the ZSFG-UCSF Department of Medicine, Co-Director of the UCSF-GIVI Center for AIDS Research (for basic and translational science), and as a member of the Leadership Committee of the UCSF AIDS Research Institute. He also recently completed terms as Interim Chief of the DEM and Chair of the ACTG Inflammation and End Organ Disease Transformative Science Group. His primary research focus is on the inflammatory consequences of HIV infection. His clinic-based translational research program seeks to understand the determinants of persistent immune activation both in the presence and the absence of antiretroviral therapy, and to assess the impact of immune activation on clinical outcomes. He collaborates extensively with a multi-disciplinary team of investigators to assess the impact of persistent immune activation despite viral suppression on mortality and chronic diseases associated with aging (i.e., cardiovascular disease) and conducts clinical trials of novel immune-based interventions designed to decrease immune activation. Dr. Hunt has also led a translational research program in Mbarara, Uganda, focused on the determinants of immune recovery during suppressive antiretroviral therapy in that setting. He also helped develop a large mucosal immunology program at Zuckerberg San Francisco General Hospital focused on the impact of HIV on gut-associated lymphoid tissue and the determinants of microbial translocation in HIV infection. In 2016, he started a laboratory in the DEM, focused on the immunologic consequences of asymptomatic CMV replication during treated HIV infection as well as the adaptive immune defects that persist in this setting in an effort to develop targets for interventions to reduce morbidity and mortality.

User Profile Bio

Displaying 226 - 250 of 318

  1. Li L, Deng X, Linsuwanon P, Bangsberg D, Bwana MB, Hunt P, Martin JN, Deeks SG, Delwart E. AIDS alters the commensal plasma virome. J Virol. 2013 Oct; 87(19):10912-5.
  2. Kembabazi A, Bajunirwe F, Hunt PW, Martin JN, Muzoora C, Haberer JE, Bangsberg DR, Siedner MJ. Disinhibition in risky sexual behavior in men, but not women, during four years of antiretroviral therapy in rural, southwestern Uganda. PLoS One. 2013; 8(7):e69634.
  3. Unemori P, Leslie KS, Hunt PW, Sinclair E, Epling L, Mitsuyasu R, Effros RB, Dock J, Dollard SG, Deeks SG, Martin JN, Maurer TA. Immunosenescence is associated with presence of Kaposi's sarcoma in antiretroviral treated HIV infection. AIDS. 2013 Jul 17; 27(11):1735-42.
  4. Jain V, Hartogensis W, Bacchetti P, Hunt PW, Hatano H, Sinclair E, Epling L, Lee TH, Busch MP, McCune JM, Pilcher CD, Hecht FM, Deeks SG. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis. 2013 Oct 15; 208(8):1202-11.
  5. Hodgkinson A, Casals F, Idaghdour Y, Grenier JC, Hernandez RD, Awadalla P. Selective constraint, background selection, and mutation accumulation variability within and between human populations. BMC Genomics. 2013 Jul 23; 14:495.
  6. Yanik EL, Napravnik S, Cole SR, Achenbach CJ, Gopal S, Olshan A, Dittmer DP, Kitahata MM, Mugavero MJ, Saag M, Moore RD, Mayer K, Mathews WC, Hunt PW, Rodriguez B, Eron JJ. Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin Infect Dis. 2013 Sep; 57(5):756-64.
  7. Huang Y, Louie A, Yang Q, Massenkoff N, Xu C, Hunt PW, Gee W. A simple LC-MS/MS method for determination of kynurenine and tryptophan concentrations in human plasma from HIV-infected patients. Bioanalysis. 2013 Jun; 5(11):1397-407.
  8. Siedner MJ, Lankowski A, Tsai AC, Muzoora C, Martin JN, Hunt PW, Haberer JE, Bangsberg DR. GPS-measured distance to clinic, but not self-reported transportation factors, are associated with missed HIV clinic visits in rural Uganda. AIDS. 2013 Jun 01; 27(9):1503-8.
  9. Yanik EL, Napravnik S, Ryscavage P, Eron JJ, Koletar SL, Moore RD, Zinski A, Cole SR, Hunt P, Crane HM, Kahn J, Mathews WC, Mayer KH, Taiwo BO, Center for Aids Research Network of Integrated Clinical Systems (CNICS) Cohort Study . Hematologic, hepatic, renal, and lipid laboratory monitoring after initiation of combination antiretroviral therapy in the United States, 2000-2010. . 2013 Jun 01; 63(2):216-20.
  10. Kaida A, Matthews LT, Kanters S, Kabakyenga J, Muzoora C, Mocello AR, Martin JN, Hunt P, Haberer J, Hogg RS, Bangsberg DR. Incidence and predictors of pregnancy among a cohort of HIV-positive women initiating antiretroviral therapy in Mbarara, Uganda. PLoS One. 2013; 8(5):e63411.
  11. Taiwo B, Hunt PW, Gandhi RT, Ellingson A, McKenna M, Jacobson JM, Gripshover B, Bosch RJ. CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy. . 2013 May 01; 63(1):101-4.
  12. Hunt PW, Shulman NS, Hayes TL, Dahl V, Somsouk M, Funderburg NT, McLaughlin B, Landay AL, Adeyemi O, Gilman LE, Clagett B, Rodriguez B, Martin JN, Schacker TW, Shacklett BL, Palmer S, Lederman MM, Deeks SG. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood. 2013 Jun 06; 121(23):4635-46.
  13. Baylor A, Muzoora C, Bwana M, Kembabazi A, Haberer JE, Matthews LT, Tsai AC, Hunt PW, Martin JN, Bangsberg DR. Dissemination of research findings to research participants living with HIV in rural Uganda: challenges and rewards. PLoS Med. 2013; 10(3):e1001397.
  14. Adakun SA, Siedner MJ, Muzoora C, Haberer JE, Tsai AC, Hunt PW, Martin JN, Bangsberg DR. Higher baseline CD4 cell count predicts treatment interruptions and persistent viremia in patients initiating ARVs in rural Uganda. . 2013 Mar 01; 62(3):317-21.
  15. Zhang X, Hunt PW, Hammer SM, Cespedes MS, Patterson KB, Bosch RJ. Immune Activation While on Potent Antiretroviral Therapy Can Predict Subsequent CD4+ T-Cell Increases Through 15 Years of Treatment. HIV Clin Trials. 2013 Mar-Apr; 14(2):61-7.
  16. Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, Bosch RJ, Lai J, Chioma S, Emad F, Abdel-Mohsen M, Hoh R, Hecht F, Hunt P, Somsouk M, Wong J, Johnston R, Siliciano RF, Richman DD, O'Doherty U, Palmer S, Deeks SG, Siliciano JD. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog. 2013 Feb; 9(2):e1003174.
  17. Overton ET, Kitch D, Benson CA, Hunt PW, Stein JH, Smurzynski M, Ribaudo HJ, Tebas P. Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis. 2013 May; 56(10):1471-9.
  18. Tsai AC, Weiser SD, Steward WT, Mukiibi NF, Kawuma A, Kembabazi A, Muzoora C, Hunt PW, Martin JN, Bangsberg DR. Evidence for the reliability and validity of the internalized AIDS-related stigma scale in rural Uganda. AIDS Behav. 2013 Jan; 17(1):427-33.
  19. Horwitz RH, Tsai AC, Maling S, Bajunirwe F, Haberer JE, Emenyonu N, Muzoora C, Hunt PW, Martin JN, Bangsberg DR. No association found between traditional healer use and delayed antiretroviral initiation in rural Uganda. AIDS Behav. 2013 Jan; 17(1):260-5.
  20. Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW. Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol. 2013; 119:51-83.
  21. Hatcher AM, Tsai AC, Kumbakumba E, Dworkin SL, Hunt PW, Martin JN, Clark G, Bangsberg DR, Weiser SD. Sexual relationship power and depression among HIV-infected women in Rural Uganda. PLoS One. 2012; 7(12):e49821.
  22. Leeansyah E, Ganesh A, Quigley MF, Sönnerborg A, Andersson J, Hunt PW, Somsouk M, Deeks SG, Martin JN, Moll M, Shacklett BL, Sandberg JK. Activation, exhaustion, and persistent decline of the antimicrobial MR1-restricted MAIT-cell population in chronic HIV-1 infection. Blood. 2013 Feb 14; 121(7):1124-35.
  23. Lauring AS, Lee TH, Martin JN, Hunt PW, Deeks SG, Busch M. Lack of evidence for mtDNA as a biomarker of innate immune activation in HIV infection. PLoS One. 2012; 7(11):e50486.
  24. Hatano H, Jain V, Hunt PW, Lee TH, Sinclair E, Do TD, Hoh R, Martin JN, McCune JM, Hecht F, Busch MP, Deeks SG. Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J Infect Dis. 2013 Jul; 208(1):50-6.
  25. Shaw JM, Hunt PW, Critchfield JW, McConnell DH, Garcia JC, Pollard RB, Somsouk M, Deeks SG, Shacklett BL. Short communication: HIV+ viremic slow progressors maintain low regulatory T cell numbers in rectal mucosa but exhibit high T cell activation. AIDS Res Hum Retroviruses. 2013 Jan; 29(1):172-7.